List of Small Molecule Pharmaceuticals Companies in New Jersey - 98

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

An early stage start-up with three products in Pre-IND phase and several complex generics in the pipeline.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

Agile Therapeutics® is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet needs of today’s women. Our product and product candidates are designed to offer women more freedom and flexibility through additional contraceptive options.

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Althera is focused on development and supply of innovative patient focused medicines. Althera’s medicines are approved and available to patients in more than 35 countries worldwide. ​Founded in 2010, we are leaders in development of innovative combination medicines in therapeutic areas of Cardiology and Diabetes, and work closely with our B2B partners in making these products available to patients in geographies across the world including all major markets in Europe and Emerging Markets including Asia, Latin America and Africa. ​Our strong R&D capabilities and network of manufacturing sites enable innovative and cost effective supply of medications to improve patient health.

Alvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world. We are passionate about making people's lives better by making high quality medicines more accessible around the world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.

ASCEND Therapeutics US, LLC is a specialty pharmaceutical company concentrating on women’s health. With a century of innovation originating with our parent company, Besins Healthcare, ASCEND Therapeutics continues to attain high standards in commercial and product development. ASCEND THERAPEUTICS U.S., LLC is a pharmaceuticals company based out of 15 Mt Kemble Ave Morristown, NJ 07960

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology-based company focusing on the development and commercialization of Branded Specialty Products and Technology Platform-based Niche Generics. Aucta is a pharmaceutical company creating enhanced products from proven molecules using the 505(b)(2) regulatory pathway. Through innovation, Aucta is creating new therapeutics, including new dosage forms, new dosing regimens, and new indications. Aucta has a clear therapeutic focus in CNS disorders, Ophthalmic, and Inhalation Therapy. We are committed to being patient-centric by continuously bringing improved forms of proven molecules into the marketplace. Aucta has operation in both New Jersey, U.S. and Shanghai, China. Our mission: Enhanced products from proven molecules!

Avet Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Avet Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centers of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Bionex’s mission is to realize the applications of bio-pharmaceutical and life sciences into commercial products and services that benefit human health. Strategically, Bionex engages in two areas of business activities. First, Bionex offers contract R&D services, from early-stage concept development, cGMP clinical supply manufacturing to full-scale commercialization, for bio-pharmaceutical products. Second, Bionex develops and out-licenses its own proprietary formulations, drug delivery technologies, and products related to medical, health food, and skin-care applications. Our expertise is focused on transdermal and transmucosal drug systems. We adopt a science-based, and yet pragmatic and out-of-box approach which often leads to fruitful outcomes, in time- and cost-effective manner. Bionex capabilities are its expertise in formulation science and analytical chemistry, full range of formulation/processing, analytical, and testing capabilities in cGMP facility, and well-connected network of industrial, academic and business consultants and advisors. Many of our in-house innovation R&D projects are funded by National Institute of Health (NIH), National Science Foundation (NSF), state grants and non-for-profit organizations.

At Castor, we believe in the power of clinical research and the power of technology. And we know that together, these forces can help extend human healthspan. To achieve this reality, we must make patient-centered clinical trials a possibility for everyone, anywhere in the world. That's why we are using technology to capture the world's research data and optimize each activity of a clinical trial. From recruitment to monitoring, our modular clinical trial platform makes it easier to design and deploy trials, enroll and engage patients, collect data and analyze results. Each module can be used individually or in unison with others, providing the ability to customize each solution to fit your needs, and grow at your own pace. That's delightful for patients, effortless for study teams, risk-free for sponsors.

Catherych Incorporated is an ingredient supplier to the natural products and nutraceuticals industry.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company’s portfolio also includes pre-clinical work on other sodium channel receptor subtypes and the Company intends to explore these and other compounds for the treatment of additional pain indications.

Claris Bio works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision-making. The company is focused on developing topical formulation technology designed to treat orphan ophthalmic disorders, such as neurotrophic keratitis, and cure corneal diseases.

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in a Phase 3 clinical trial enrolling patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for five additional years of QIDP market exclusivity in the event of U.S. approval. It is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers.

Couragene believes that delivery of gene and biologic therapies should be safer and more efficient. Delivery of genome modification therapies to brain is further complicated by the physiological barriers. Couragene's STEP (Stimuli-responsive Traceless Engineering Platform) technology has demonstrated great potential to overcome the delivery hurdles for treatment of various diseases, including neurogenetic disorders.

Validation Consulting

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.us. See our community guidelines here: https://bit.ly/4fLkZS8

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. We develop and assess therapeutics based upon their ability to make a meaningful impact for patients and their treatment experiences. We invest in proven and promising therapeutics at various stages of development and advance them through clinical and regulatory processes with the goal of commercializing improved treatment options for patients and the healthcare providers who treat them.

Elite Pharmaceuticals is a pharmaceutical company that specializes in drug manufacturing and healthcare solutions.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company's initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for IBD, a mechanism already validated by a commercially available antibody. Ensho's assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program in UC with NSHO-101, the lead asset in the company's pipeline.

Enzon is a New Jersey-based biopharmaceutical company that develops and commercializes medicines for the treatment of cancer.

Powering relentless science by developing and commercializing first-in-class treatments to address debilitating and potentially fatal diseases, including COVID-19 and other infectious diseases; autoimmune diseases including rheumatoid arthritis; cachexia associated with AIDS or cancer; and topical non-invasive treatments for sight-robbing retinal diseases.

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries around the world.

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Generics

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Biotech company specializing in drug discovery for hematologic diseases

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Company’s lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.

Ingenio Diagnostics (ID), a Genesis Drug Discovery and Development (GD3) Member Company, combines experience in Pharmaceutical, Biotechnology, and CRO services with a clinical diagnostic laboratory's licensure and accreditation. We deliver clinical diagnostic laboratory services and specialty testing with the additional benefit of dedicated quality assurance & quality control division. Our highly-skilled team of scientists, clinical, and operations personnel have extensive experience analyzing a wide variety of patient specimen types, spanning multiple analytical platforms in many therapeutic areas.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Integrated Analytical Solutions, Inc. (IAS), a Genesis Drug Discovery and Development (GD3) Company, is a contract research organization that provides analytical, bioanalytical and drug metabolism services to the pharmaceutical industry. The company was founded in 2004 to fill an unmet need for expert, economical and timely analytical services. Our laboratory is a state-of-the-art facility located in Berkeley, California within one of the world's most active life science research clusters (San Francisco Bay Area). The company is comprised of two operating divisions: GxP and Research and Discovery (R&D). The separate divisions enable the company to accommodate a wide range of projects and deliver fit-for-purpose methods based on each client's specific stage of development and budget. IAS offers each and every client boutique-level attention while providing cost-effective and timely data. Our track record for outstanding service and our collaborative spirit have resulted in long-lasting relationships with biopharmaceutical groups and academic laboratories around the globe.

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

WHO WE ARE iQure Pharma is uniquely positioned in developing new therapeutics solutions by bridging inventions stemming mostly from academia research with pharma industry, founded by entrepreneurs with strong pharmaceutical and financial industry background. OUR CORE COMPETENCIES Scouting for innovative compounds coming out of research from unmined academic sources. Evaluating out-licensing opportunities with big pharma and biotech for medical and commercial attractive targets. Selecting from that pool those compounds with a significant attractive target profile, which can support a future commercialization process. Driving and leading preclinical and clinical development activities, ensuring regulatory and quality compliance in all development tasks, while never losing focus on the final beneficiaries’ needs: the patients. Securing the required investment activities by assisting our investors in placing their funding in the most commercially viable therapies with attractive market potential and addressing clearly defined clinical needs.

iVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative therapies for clear vision and healthier eyes.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

Jeiven Pharmaceutical Consulting, Inc. (JPC) brings over twenty years of experience to our goal of providing pharmaceutical, biotechnology, medical device and dietary supplement companies with an unparalleled level of service and dedication to ensure the success of their projects. Our clients, which range from the small start-up to the large pharmaceutcial firms, come back to us because they know we will provide them with the highest level of service in combination with the expertise of our skilled consultants. The hallmark of our success has been our outstanding customer satisfaction and client retention. We take pride in providing, above all else, Reliable Guidance to clients of all sizes. Our areas of expertise include: 1) Clinical Trial Materials Project Management 2) Quality Assurance and Compliance 3) Auditing (contractors, suppliers, due diligence audits, mock-PAI audits, general GMP, GLP, GCP audits) 4) Training (GMP, GLP, GCP, DEA) 5) Regulatory Submissions (IND, IDE, CMC, 510(k), PMA, NDA, ANDA, eCTD) 6) Authoring SOPs and Quality Manuals 7)Formulation Development 8) Scale-up, Optimization and Method Transfer 9) Equipment Qualification 10) Analytical Method Development 11) Combination Drug / Device Products 12) Due Diligence Services for Venture Capital Firms 13) Process / Facilities Validation 14) Staffing 15) Comparator Drug Sourcing 16) Organizing the Clinical Supplies Support Group (CSSG) 17) Medical Device and In-vitro Diagnostics

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

J-STAR Research, Inc. is a contract chemistry organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. J-STAR is a leading provider of services in organic synthesis problem solving, early phase non-GMP and GMP manufacturing and crystallization R&D. While high quality synthetic chemistry and process research services continue to be J-Star’s foundation, the company has steadily added and continues to expand in the areas of QC, GMP and QA, Crystallization R&D, Solid Form and Polymorph Screening, Catalysis Screening + Enabling Technology, Highly Potent Compound Handling (HPAPI), Impurity Isolation and Structural Elucidation by NMR and HR-LC/MS and Preformulation for Drug Product Development. J-Star’s expert team of scientists and professionals coupled with solid industrial experience, a track record of dependability, and over 70,000 SF of well-equipped laboratories across two New Jersey research facilities ensures that all projects are delivered in full, on time and with rigorous quality.

Kashiv BioSciences manufactures drug delivery systems and specialty drug products for the treatment of debilitating diseases.

Headquartered in Somerset, NJ with offices around the world, LabVantage Solutions, Inc. provides laboratories with a comprehensive portfolio of informatics products and services, including LIMS (Laboratory Information Management System), integrated electronic laboratory notebook (ELN) and business intelligence. Our industry-leading solutions and services are the result of 35+ years of experience in laboratory informatics. We leverage that knowledge with state-of-the-art technology to help organizations redefine and optimize the way their laboratories conduct business. LabVantage has a solid track record of delivering return on investment to laboratories of all sizes. Our capabilities extend to legacy system migration, global laboratory harmonization, and laboratory business intelligence derived from disparate sites and systems. LabVantage delivers the best technical and domain expertise available to help you drive the success of your business. To find out more, visit us at: http://www.labvantage.com.

Leading Pharma, LLC is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Our products are available in various dosage forms across many therapeutic areas under the Leading label. Product and Customer Related Inquiries – MEDICAL INFORMATION · Report Adverse Events / Side Effects · Report Product Complaints · Submit Medical Inquiries · Report Product Overdose and Poisoning Please contact us in the given details. By Phone: (844)-740-7500 By Fax: (973)-276-9656 By Email: micc_leadingpharma@mitoconbiopharma.com

Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics has been granted Orphan Drug Designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

LipoSeuticals is a specialty pharmaceutical company that engages in the development, manufacturing and commercialization of parenteral drug products.

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

MedChemExpress LLC, or MedChemExpress (MCE), is a biotech company based in New Jersey, USA, with locations in Princeton and Monmouth Junction. The company specializes in supplying high-quality research chemicals and biochemicals, including a vast selection of bioactive molecules such as selective inhibitors and recombinant proteins. These products are essential for pharmaceutical and life sciences research. MCE offers a variety of services to support research and development in the life sciences sector. Their services include custom synthesis for various compounds, protein expression and purification, and a comprehensive compound screening platform. They also provide molecular biology tools and cell biology services, which encompass cell culture and analysis. With a catalog of over 50,000 products, MedChemExpress is recognized for its contributions to drug discovery and research, serving a diverse global customer base in academia and industry.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Mestastop Solutions is a biotechnology startup based in India, focused on addressing cancer metastasis. The company aims to develop innovative solutions to combat the spread of tumors, which significantly contributes to cancer-related deaths worldwide. Mestastop has gained global recognition for its research, presenting its work at major international conferences such as the American Association of Cancer Research Annual Conference and the European Association of Cancer Research. The company is involved in diagnostics and discovery related to cancer metastasis, with a focus on small molecule drugs to tackle distant metastasis. Mestastop's approach includes unraveling the biology of metastasis to create targeted treatments. The company has been vetted by the scientific outsourcing platform Science Exchange and is recognized as an authorized service provider, underscoring its credibility in the field.

Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Novelstar Pharmaceuticals Inc., founded in August, 2018, is a Company of Fosun Pharma focusing on the development of special pharmaceutical products of NDA and ANDA with advanced drug delivery systems. Our parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is a leading health and medical industry group in China. Fosun Pharma has a mission to promote human health. Its business covers the whole pharmaceutical industry chain, including drug manufacturing and R & D, medical services, medical device and medical diagnostics, pharmaceutical distribution and retail. Fosun Pharma has a state-of-the-art innovative technology center and an international R & D team. It continuously focuses on innovative research and development in cardiovascular, central nervous system, blood system, metabolism and digestive system, anti-infective and anti-tumor therapeutic fields. Facing the future, Fosun Pharma will adhere to the brand philosophy of "continuing to innovate and enjoy health" and continue to adhere to the development strategy of "endogenous growth, outward expansion and integrated development", and strive to become the first-class enterprise in the global mainstream medical and health market. Learn more on the FosunPharma website: https://www.fosunpharma.com/en/

Nuvectis Pharma is a biopharmaceutical company that focuses on developing novel targeted therapeutics for cancer treatment, including the oral small molecule inhibitor NXP800 targeting the Heat Shock Factor 1 pathway.

Odin Pharmaceuticals LLC is a sterile pharmaceutical company that develops injectable and ophthalmic drugs for the US marketplace.

Optimeos Life Sciences is pioneering a novel targeted gene delivery approach to advance medical treatment and patient care.

Organon is a global healthcare company with a portfolio of therapies and products in women’s health, biosimilars, and established medicines across a wide array of conditions and diseases. Our mission is to deliver impactful medicines and solutions for a healthier every day. This site is intended for residents of the United States and its territories. You are reminded to protect yourself against recruiting fraud from individuals, organizations or other entities claiming to represent Organon. All official Organon recruitment emails will come from accounts formatted as name@organon.com or organon@workday.com, and Organon will never conduct interviews by chat or email, or make job offers through social media or online forums. All candidates for roles at Organon will first meet with a recruiter and interview team, via Teams or in person. Organon will never ask you to make financial transactions on its behalf or ask you to receive or ship packages or goods. For more information on adverse event reporting, visit http://bit.ly/AEReporting. To read our community guidelines, visit http://bit.ly/OrganonCommunityGuidelines. Follow us on Twitter at Organon (@OrganonLLC). Follow us on Instagram at Organon (@OrganonLLC).

There are two Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Palatin (NYSE American: PTN) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system. The melanocortin system is involved in regulating important physiological activities such as food intake and energy balance, desire and arousal, and the resolution of harmful inflammation. We are the first company to obtain FDA approval for a melanocortin based therapeutic, Vyleesi®, a treatment for women with hypoactive sexual desire disorder (HSDD). With the successful development of Vyleesi® and our extensive experience in the development of melanocortin based therapeutics, we are now focused on developing therapeutics that take advantage of the key role that the melanocortin system plays in the resolution of harmful inflammation. This has the potential to treat diseases that affect the eye, gastrointestinal system and the kidney. Our most advanced ocular product is PL9643, a topical treatment for dry eye disease, which is targeted to enter Phase 3 clinical trials in 2H 2021. We also have therapeutics in earlier stages of development for ophthalmic indications such as non-infectious uveitis, retinopathies and corneal diseases. Therapeutics that modulate the activity of the melanocortin system will have broad utility and to establish this, we are planning to conduct proof of concept clinical studies in ulcerative colitis and kidney disease. Vyleesi® is the first and only on-demand, FDA-approved treatment for premenopausal women suffering with HSDD, which affects 1 in 10 pre-menopausal women. Learn about this condition here: https://www.unblush.com/ To learn more about Vyleesi®, including Important Safety Information, visit here: https://www.vyleesi.com/ We are very excited by the tremendous potential our therapeutics have to positively impact the lives of patients and the value we can build for our shareholders. Find more information about our programs: www.palatin.com

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

At Petros, we are bringing new approaches to the most challenging conditions in men's health. We seek to understand the various health phases throughout a man’s journey. We collaborate with researchers, scientists, medical thought leaders and payers to ensure our therapies aid in restoring men’s body function to vitality. Please see the full Prescribing Information and Patient Information: https://stendra.com/wp-content/uploads/2022/04/stendra-prescribing-information.pdf https://stendra.com/wp-content/uploads/2022/04/stendra-patient-information.pdf

We are drug development experts that use a simple and cost-effective business model to provide targeted expertise and broad development experience to help you move forward while managing risk, cost and time.

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

We bring an aggregate 80+ years of diverse experience in solving complex issues with preclinical drug candidates by identifying creative and innovative solutions for key problems with drug delivery, exposure, chemical and physical stability, drug metabolism, safety, and toxicity. IP expert witness.

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and significant mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases. - The company's lead product, SANGUINATE™, is focused on treating the comorbidities of sickle cell disease and hemorrhagic stroke - Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy - Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer ___________

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Our (re)Vision: Bring impactful ophthalmic medicines to as many patients as possible as quickly as possible. The company is pursuing products that address unmet needs, can be priced for access, and still have substantial commercial potential. reVision Therapeutics, Inc. was founded in 2018 to develop medicines with high disease impact, and rapidly get those medicines to patients. The company prioritizes areas of unmet or poorly met needs in ophthalmic disorders by repurposing approved or rescuing shelved drugs that could change patients’ lives. Repurposing or rescuing drugs allows for faster development at a reduced cost. Our lead program is a product for Stargardt disease, a retinal degenerative disease that often begins in childhood. Our candidate is a repurposed, GRAS (generally recognized as safe) cyclodextrin delivered intravitreally that could work as a first-line therapy or in combination with other products currently in development. It can be developed fast and produced at a relatively low cost. Other targets include a repurposed drug for dry eye disease, a rescued therapy for proliferative vitreoretinopathy, and a combination product to treat intraocular pressure.

RVL Pharmaceuticals (previously named Osmotica Pharmaceutical; Nasdaq: OSMT) is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population. We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.

Sciecure Pharma, Inc. is a US based, specialty pharmaceutical company, driven by a highly dedicated team, with 10,000 sq-ft laboratory and office space in Monmouth Junction, New Jersey. The current focus of the company is on research and development of high barrier drug products.

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Signum’s phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. Signum has established a robust IP portfolio in the area of Signal Transduction Modulators (STMs). Signal transduction networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Signum has identified agents that perturb the two most central of these global regulatory mechanisms: G-Protein-Mediated membrane receptor signaling and Protein phosphorylation. G-Protein modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct stressful imbalances that can be detrimental to health and well-being.

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders.

SkinAxis is a biotechnology company that provides multicellular skin equivalent systems that reproduce the physiological properties of human skin tissues. These models represent the response of human skin to drug and active ingredient treatment more accurately then animal models. SkinAxis multicellular three-dimensional tissues can be customized using cell types engineered to specifically express gene reporter systems. These advanced models allow the faster, more sensitive, and more accurate assessment of the preclinical activity profile of drugs and active compounds. All products by SkinAxis are made in Inited States of America We seek to provide and develop solutions for cosmetic, biotechnology, pharmaceutical, chemical and diagnostic companies and academic laboratories interested in active ingredient testing and drug discovery

Skunkworx Bio (SKWX) is a drug discovery powerhouse obsessed with building novel therapeutics for major unmet medical needs. SKWX expertise comes from two decades of molecular engineering experience with leaders in the field of biologic intervention. The company’s unique and proprietary technical platform allows for the generation of new biological entities unknown to biology and outside the human repertoire of possibilities.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.  Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203). Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®.  We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).

Sunrise Pharma is a premier provider of safe and affordable generic medicines. Sunrise was founded and is based in the United States. Our products appear in various dosage forms across multiple therapeutic areas. We market products to all pharmaceutical channels including local and national retailers, wholesalers, distributors, health systems, and government. We understand the role of medicine in our society and we are wholly committed to supplying top notch quality products to the US pharmaceutical market. Our aim is to provide a diverse portfolio of safe and affordable generic medications to millions of patients to lead a happier and healthier life.

Tara Innovations LLC is formulation contract research organization (CRO). We specialize in product development, technology management, analysis, and process development. We do preformulation and pharmaceutical consulting. We are expert in nanotechnology.

TAXIS Pharmaceuticals is a biotech company devoted to combatting the serious and deadly societal threat of antibiotic resistance by creating therapies that address the root cause of the issue. We're developing therapies that, when used in combination with FDA-approved antibiotics, are intended to restore the efficacy of those medications. We currently have one investigational therapy that has completed Ph1 human trials, and several additional products in the pipeline.

We are an independent, full-service, family-owned CRO specializing in dermatology since 1944. We manage global phase 2/3 trials in conjunction with our standalone phase I unit. Our structure and experience allow us to approach each and every study with agility and innovation, providing our sponsors with a truly bespoke turnkey solution. We are not your traditional CRO.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company’s lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company’s lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer’s disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

We Specialize in Urology and Women’s Health Care.Pain, urgency, frequency. Every day, urologic disorders continue to affect the lives of people all around us. Vaneltix is focused on providing immediate relief for patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), a disease of the lower urinary tract that predominantly affects women.

Vivozon is a pharmaceutical drug development company.

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.

Generic injectables

YARAL Pharma Inc. is the US subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they're cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service.

Zena Therapeutics is a drug discovery company, spun-out of Rutgers University, designing new medications for mental health and addiction by improving safety profiles. Currently the work at Zena focuses on acute anxiolytic compounds that do not increase the risk of overdose if taken concomitantly with other central nervous system depressing substances such as opioids and alcohol.